Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
Nov 2020
Historique:
pubmed: 11 9 2020
medline: 11 9 2020
entrez: 10 9 2020
Statut: ppublish

Résumé

In the original article, the reference 4 has been published and cited incorrectly.

Identifiants

pubmed: 32910418
doi: 10.1007/s12325-020-01480-1
pii: 10.1007/s12325-020-01480-1
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

4754

Commentaires et corrections

Type : ErratumFor

Auteurs

Joseph Chen (J)

Global Product Development, Pfizer Oncology, New York, NY, USA. joseph.chen@pfizer.com.

Huiping Xu (H)

Global Product Development, Clinical Pharmacology, Pfizer Oncology, La Jolla, CA, USA.

Sylvester Pawlak (S)

Global Product Development, Pfizer Inc., New Haven, CT, USA.

Leonard P James (LP)

Global Product Development, Pfizer Oncology, New York, NY, USA.

Gerson Peltz (G)

Safety Surveillance and Risk Management, Pfizer Oncology, Groton, CT, USA.

Kimberly Lee (K)

Global Product Development, Pfizer Inc., Groton, CT, USA.

Katherine Ginman (K)

Global Product Development, Pfizer Inc., South Lyon, MI, USA.

Michelle Bergeron (M)

Global Product Development, Pfizer Inc., Groton, CT, USA.

Yazdi K Pithavala (YK)

Global Product Development, Clinical Pharmacology, Pfizer Oncology, La Jolla, CA, USA.

Classifications MeSH